GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Additional Paid-In Capital

ME Therapeutics Holding (XCNQ:METX) Additional Paid-In Capital : C$0.00 Mil(As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Additional Paid-In Capital?



ME Therapeutics Holding Additional Paid-In Capital Historical Data

The historical data trend for ME Therapeutics Holding's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Additional Paid-In Capital Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Additional Paid-In Capital
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Additional Paid-In Capital Get a 7-Day Free Trial - - - - -

ME Therapeutics Holding Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

ME Therapeutics Holding Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines